On Oct. 20, 2025, ACG, the world’s most integrated provider of solid-dosage solutions, announced a $200 million phased investment to establish its first empty-capsule manufacturing operations in the United States. The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta, Georgia, with a second phase of $100 million planned to expand capacity and capabilities in the region. The investment is expected to create more than 200 jobs, with operations targeted to begin in early 2027.

ACG will establish dedicated facilities to manufacture gelatin and vegetarian (HPMC) hard-shell capsules, designed and operated to the highest global standards of quality, safety, and regulatory compliance. The program advances ACG’s Make it Better commitment and complements the company’s U.S. ecosystem spanning capsules, barrier packaging materials, processing and encapsulation machinery, visual inspection, and traceability solutions—supported by nationwide sales and service.

ACG has operated in the United States for more than 25 years, with North American headquarters in Piscataway, N.J., manufacturing liquid fill capsules in Chadds Ford, Pa., with several warehouses across the United States, and sales and service teams nationwide.